Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial

The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc PSTV to proceed to the eighth cohort of Phase 1 dose-escalation ReSPECT trial evaluating Rhenium NanoLiposome (RNL) for recurrent glioblastoma.
The eighth cohort of the ReSPECT trial will implement a 40% increase in total radioactivity.
The planned infused dose will be 31.2 millicuries in a volume of 12.3 milliliters (increased from 22.3 millicuries and 8.8 milliliters, respectively, used in cohort seven).
The planned maximum flow rate will not change.
Price Action: PSTV shares are higher by 2.94% at $2.80 during the premarket session on the last check Wednesday.